Breast Milk Pharmacokinetics of Efavirenz and Breastfed Infants' Exposure in Genetically Defined Subgroups of Mother-Infant Pairs: An Observational Study

Clinical Infectious Diseases

Volumn 61, Issue 3, 2015, Pages 453-463

  Olagunju, Adeniyi ^a,b   Bolaji, Oluseye ^b   Amara, Alieu ^a   Waitt, Catriona ^a   Else, Laura ^a   Adejuyigbe, Ebunoluwa ^b   Siccardi, Marco ^a   Back, David ^a   Khoo, Saye ^a   Owen, Andrew ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b OBAFEMI AWOLOWO UNIVERSITY   (Nigeria)

Author keywords

breast milk; CYP2B6 516G>T; efavirenz; infant exposure; pharmacokinetics

Indexed keywords

ABACAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; NEVIRAPINE; TENOFOVIR DISOPROXIL; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CYTOCHROME P450 2B6;

ABCB1 GENE; ABCB5 GENE; ABCG2 GENE; ABSENCE OF SIDE EFFECTS; ADULT; ANTIVIRAL THERAPY; ARTICLE; BREAST FEEDING; BREAST MILK; CYP2A6 GENE; CYP2B6 GENE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE; GENETIC ASSOCIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MATERNAL PLASMA; MOTHER CHILD RELATION; NR1I3 GENE; OBSERVATIONAL STUDY; PERINATAL DRUG EXPOSURE; PHARMACOGENETICS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT RESPONSE; VERTICAL TRANSMISSION; ADOLESCENT; BLOOD; CHEMISTRY; GENETICS; HIV INFECTIONS; METABOLISM; NEWBORN; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; BREAST FEEDING; CYTOCHROME P-450 CYP2B6; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; LINEAR MODELS; MILK, HUMAN; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; YOUNG ADULT;

EID: 84938596203     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ317     Document Type: Article

References (38)

1. WorldHealth Organisation. Rapid advice: infant feeding in the context of HIV. Geneva: World Health Organisation, 2009. Available at: http:// whqlibdoc.who.int/publications/2009/9789241598873-eng.pdf. Accessed 30 September 2014.
2. Cames C, Saher A, Ayassou KA, Cournil A, Meda N, Simondon KB. Acceptability and feasibility of infant-feeding options: experiences of HIV-infected mothers in the World Health Organization Kesho Bora mother-to-child transmission prevention (PMTCT) trial in Burkina Faso. Matern Child Nutr 2010; 6:253-65.
3. World Health Organisation. Guidelines on HIV and infant feeding. Principles and recommendations for infant feeding in the context of HIV and a summary of evidence. Geneva: World Health Organisation, 2010. Available at: http://whqlibdoc.who.int/publications/2010/ 9789241599535-eng.pdf. Accessed 30 September 2014.
4. Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM. Influence of infant-feeding patterns on early mother-to-child transmission of HIV-1 in Durban, South Africa: a prospective cohort study. South African Vitamin A Study Group. Lancet 1999; 354:471-6.
5. Ngwende S, Gombe NT, Midzi S, Tshimanga M, Shambira G, Chadambuka A. Factors associated with HIV infection among children born to mothers on the prevention of mother to child transmission programmeat Chitungwiza Hospital, Zimbabwe, 2008. BMC Public Health 2013; 13:1181.
6. Kafulafula G, Hoover DR, Taha TE, et al. Frequency of gastroenteritis and gastroenteritis-associated mortality with early weaning in HIV-1-uninfected children born to HIV-infected women in Malawi. J Acquir Immune Defic Syndr 2010; 53:6-13.
7. Asbjornsdottir KH, Slyker JA, Weiss NS, et al. Breastfeeding is associated with decreased pneumonia incidence among HIV-exposed, uninfected Kenyan infants. AIDS 2013; 27:2809-15.
8. World Health Organisation. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: programmatic update. Available at: http://whqlibdoc.who.int/hq/2012/WHO-HIV-2012. 6-eng.pdf. Accessed 30 September 2014.
9. Centers for Disease Control and Prevention. Impact of an innovative approach to prevent mother-to-child transmission of HIV-Malawi, July 2011-September 2012. MMWR Morb Mortal Wkly Rep 2013; 62:148-51.
10. World Health Organisation. PMTCT strategic vision 2010-2015. Preventing mother-to-child transmission of HIV to reach the UNGASS and Millennium Development Goals. Available at: http://www.who.int/ entity/hiv/pub/mtct/strategic-vision.pdf. Accessed 30 September 2014.
11. World Health Organisation. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available at: http://www.who.int/iris/bitstream/10665/85321/1/9789241505727- eng.pdf. Accessed 30 September 2014.
12. Panel on Antiretroviral Therapy andMedical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Rockville: US Department of Health and Human Services (HHS), 2014. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/ pediatricguidelines.pdf. Accessed 30 September 2014.
13. Schneider S, Peltier A, Gras A, et al. Efavirenz in human breast milk, mothers', and newborns' plasma. J Acquir Immune Defic Syndr 2008; 48:450-4.
14. Gandhi M, Mwesigwa J, Aweeka F, et al. Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding. J Acquir Immune Defic Syndr 2013; 63:578-84.
15. Wilson JT, Brown RD, Cherek DR, et al. Drug excretion in human breast milk: principles, pharmacokinetics and projected consequences. Clin Pharmacokinet 1980; 5:1-66.
16. Ito S. Drug therapy for breast-feeding women. N Engl J Med 2000; 343:118-26.
17. Olagunju A, Bolaji OO, Amara A, et al. Development, validation and clinical application of a novel method for the quantification of efavirenz in dried breast milk spots using LC-MS/MS. J Antimicrob Chemother 2015; 70:555-61.
18. Rakhmanina NY, van den Anker JN. Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol 2010; 6:95-103.
19. Barreiro P, Fernandez-Montero JV, de Mendoza C, Labarga P, Soriano V. Pharmacogenetics of antiretroviral therapy. Expert Opin Drug Metab Toxicol 2014; 10:1119-30.
20. Olagunju A, Owen A, Creesey TR. Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding. Pharmacogenomics 2012; 13:1501-22.
21. Amara AB, Else LJ, Tjia J, et al. Avalidated method for quantification of efavirenz in dried blood spots using high-performance liquid chromatography-mass spectrometry. Ther Drug Monit 2015; 37:220-8.
22. KromdijkW, Mulder JW, Rosing H, Smit PM, Beijnen JH, Huitema AD. Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. J Antimicrob Chemother 2012; 67:1211-6.
23. Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009; 169:505-14.
24. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother 2004; 48:437-43.
25. Acosta EP, Limoli KL, Trinh L, et al. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data. Antimicrob Agents Chemother 2012; 56:5938-45.
26. Croom EL, Stevens JC, Hines RN, Wallace AD, Hodgson E. Human hepatic CYP2B6 developmental expression: the impact of age and genotype. Biochem Pharmacol 2009; 78:184-90.
27. ter Heine R, Scherpbier HJ, Crommentuyn KML, et al. A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations. Antiviral Therapy 2008; 13:779-87.
28. Cressey TR, Stek A, Capparelli E, et al. Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum. J Acquir Immune Defic Syndr 2012; 59:245-52.
29. Dooley KE, Denti P, Martinson N, et al. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection. J Infect Dis 2015; 211:197-205.
30. Palombi L, Pirillo MF, Andreotti M, et al. Antiretroviral prophylaxis for breastfeeding transmission in Malawi: drug concentrations, virological efficacy and safety. Antivir Ther 2012; 17:1511-9.
31. Zeh C, Weidle PJ, Nafisa L, et al. HIV-1 drug resistance emergence among breastfeeding infants born to HIV-infected mothers during a single-arm trial of triple-antiretroviral prophylaxis for prevention of mother-to-child transmission: a secondary analysis. PLoS Med 2011; 8:e1000430.
32. Salazar-Gonzalez JF, Salazar MG, Learn GH, et al. Origin and evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing. J Virol 2011; 85:2751-63.
33. Gantt S, Carlsson J, Heath L, et al. Genetic analyses of HIV-1 env sequences demonstrate limited compartmentalization in breast milk and suggest viral replication within the breast that increases with mastitis. J Virol 2010; 84:10812-9.
34. Van de Perre P, Rubbo PA, Viljoen J, et al. HIV-1 reservoirs in breast milk and challenges to elimination of breast-feeding transmission of HIV-1. Sci Transl Med 2012; 4:143sr3.
35. Kuhn L, Hunt G, Technau KG, et al. Drug resistance among newly diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis. AIDS 2014; 28:1673-8.
36. Micek MA, Dross S, Blanco AJ, et al. Transmission of nevirapineresistant HIV type 1 via breast milk to infants after single-dose nevirapine in Beira, Mozambique. J Infect Dis 2014; 210:641-5.
37. KromdijkW, Mulder JW, Rosing H, Smit PM, Beijnen JH, Huitema AD. Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz. J Antimicrob Chemother 2012; 67:1211-6.
38. Rezk NL, Abdel-Megeed MF, Kashuba AD. Development of a highly efficient extraction technique and specific multiplex assay for measuring antiretroviral drug concentrations in breast milk. Ther Drug Monit 2007; 29:429-36.